Immunohistochemistry and Immunofluorescence for Proteinase Antibodies

Proteinase IHC antibody workflows sit at the intersection of tissue histology and paralogue-specific detection. Neither is straightforward on its own, and combining them adds specific technical demands: the antigen retrieval step that recovers epitopes masked by formalin cross-linking is the same step that can alter epitope accessibility for domain-specific proteinase antibodies, the amplification chemistry that produces bright IHC signal is the same chemistry that can produce non-specific staining if blocking is imperfect, and the multi-channel IF workflows that give the best proteinase functional-state resolution are also the workflows most sensitive to secondary antibody cross-reactivity. This overview walks through the technique and identifies where proteinase-specific decisions matter.

A note on validation status: TPB's catalog antibodies were developed and are validated primarily for Western blot and ELISA. IHC and IF validation is a current internal program; individual product pages will note validation status as it is completed. This overview page is a technique reference — it establishes the workflow and the proteinase-specific considerations — rather than a claim that TPB antibodies are validated for IHC or IF use.

IHC vs IF — the technique-level distinction

Immunohistochemistry (IHC) and immunofluorescence (IF) share the same core principle: an antibody bound to a target in a tissue section is detected by a labelled secondary antibody. The difference is in the label. IHC uses an enzyme-conjugated secondary (typically HRP or alkaline phosphatase) that catalyses a chromogenic reaction, producing a coloured precipitate visible by standard brightfield microscopy. IF uses a fluorophore-conjugated secondary detected on a fluorescence microscope.

The consequences of this choice extend through the workflow. IHC is compatible with archival paraffin-embedded tissue, produces a permanent stain, is amenable to high-throughput automated staining, and requires only brightfield microscopy for interpretation. IF is compatible with frozen sections and cell culture, supports true multiplexing (multiple channels imaged simultaneously), gives subcellular resolution, and is required for quantitative co-localisation studies — but requires fluorescence microscopy and is more susceptible to signal degradation over time.

Tissue preparation — FFPE vs frozen

Tissue preparation choice affects almost every subsequent step. The two dominant approaches are formalin-fixed paraffin-embedded (FFPE) and frozen (cryosectioned) tissue.

FFPE tissue

Tissue is fixed in 10% neutral-buffered formalin (typically overnight at room temperature), dehydrated through graded alcohols, cleared in xylene, and embedded in paraffin wax. Sections are cut on a microtome (typically 4-6 μm), dried onto slides, and stored indefinitely. Formalin fixation cross-links proteins via methylene bridges, preserving tissue architecture but masking many epitopes. Antigen retrieval is required to reverse the cross-linking sufficiently for antibody access.

FFPE advantages: excellent tissue morphology, archival stability (decades in the block), compatibility with essentially all pathology workflows, high throughput. FFPE disadvantages: fixation-dependent epitope masking, antigen retrieval required, some epitopes irreversibly damaged by fixation.

Frozen tissue

Tissue is snap-frozen (typically in isopentane cooled by liquid nitrogen), sectioned on a cryostat (5-10 μm), briefly fixed on the slide (acetone, methanol, or 4% paraformaldehyde), and stained. Frozen sections preserve most epitopes in near-native form but have inferior morphology compared to FFPE and cannot be archived long-term at room temperature.

Frozen advantages: minimal epitope damage, most native fold preserved, suitable for antibodies that fail on FFPE. Frozen disadvantages: poorer morphology, technically demanding sectioning, limited archival storage.

Choice depends on the epitope and the tissue availability. For FFPE-only clinical archives, FFPE is the only option and antigen retrieval must be optimised. For prospectively collected research tissue, frozen is often the safer choice for proteinase antibodies whose epitopes may be sensitive to formalin cross-linking.

Antigen retrieval considerations

Antigen retrieval reverses formalin-induced cross-linking to expose masked epitopes. Two main approaches: heat-induced epitope retrieval (HIER) and enzymatic retrieval.

Heat-induced epitope retrieval (HIER)

Sections are heated in an aqueous buffer to boiling or above. Standard buffers: citrate (pH 6.0) or Tris-EDTA (pH 9.0). Different targets respond differently to the two buffers — citrate pH 6.0 works for most targets; Tris-EDTA pH 9.0 is required for some epitopes and gives cleaner background for others. Heat is applied by pressure cooker (2-5 minutes at ~120°C), microwave (10-20 minutes at boiling), or water bath (30-60 minutes at 95°C).

Enzymatic retrieval

Sections are digested with proteinase K, trypsin, or pepsin. Effective for some targets that fail HIER, particularly those with epitopes in extracellular matrix contexts. Requires careful timing — over-digestion destroys morphology.

Proteinase-specific considerations for antigen retrieval

Because proteinase antibodies frequently recognise epitopes in the propeptide, at the catalytic site, or at C-terminal regulatory domains, and each of these has different sensitivity to formalin cross-linking, retrieval optimisation is typically antibody-specific. As a starting point: try HIER citrate pH 6.0 first; if signal is absent or too weak, try HIER Tris-EDTA pH 9.0; if both fail and morphology allows, try mild enzymatic retrieval. Testing on positive-control tissue (a tissue known to strongly express the target) at each retrieval condition allows condition selection before the experimental tissue is committed.

Blocking and permeabilisation

Blocking saturates non-specific binding sites on the tissue and on the slide. Standard blocking: 5-10% normal serum from the species that the secondary antibody was raised in (e.g., 10% normal goat serum for goat anti-rabbit secondary), sometimes combined with 1% BSA and 0.1-0.3% Triton X-100 for permeabilisation.

For intracellular targets, permeabilisation is required to allow antibody access. Triton X-100 (0.1-0.3%) is the standard detergent; saponin (0.05-0.1%) is used when membrane cholesterol needs to be preserved. For membrane-anchored proteinases like ADAMs, permeabilisation choice affects whether the antibody detects the intracellular or extracellular pool — for surface-only detection, non-permeabilised staining; for total protein, permeabilised.

Endogenous enzyme blocking (IHC only)

For chromogenic IHC with HRP-based detection, endogenous peroxidase activity (in erythrocytes and some tissues) must be quenched — typically with 3% hydrogen peroxide, 10 minutes at room temperature. For alkaline phosphatase-based detection, levamisole is added to the substrate to inhibit endogenous alkaline phosphatase.

Primary antibody application

The primary antibody is diluted in blocking buffer (or in TBS with 1% BSA for lower background) at a dilution determined by titration. IHC and IF dilutions are typically 5-10× more concentrated than Western blot dilutions for the same antibody — e.g., a WB dilution of 1:1000 typically translates to an IHC dilution of 1:100 to 1:200.

Incubation: overnight at 4°C is standard for most protocols. 1 hour at room temperature works for high-titre antibodies but is more variable. Humidified chamber to prevent drying is essential.

Titrate every antibody in every tissue type before running the definitive experiment. What worked at 1:100 on cell culture may need to be 1:50 on FFPE tissue. See the antibody specificity validation guide for IHC-specific validation considerations.

Detection systems

The choice of detection system depends on IHC vs IF and on sensitivity requirements.

Controls for IHC and IF

Controls in IHC and IF are more elaborate than in Western blot because morphological context can distract from the specificity question. A minimum control panel:

• Positive control tissue: A tissue known to strongly express the target (e.g., stimulated macrophage-containing tissue for MMP-9). Confirms the antibody works in the workflow.
• Negative control tissue: A tissue known to lack the target. Ideal is a knockout mouse tissue; alternative is a species-mismatched tissue where the antibody should not cross-react.
• No-primary control: The same protocol run without the primary antibody. Signal here is entirely secondary + detection background.
• Isotype control: A non-specific antibody of the same isotype and concentration as the primary. Confirms that background is not from the specific host species.
• Peptide competition: For peptide-immunogen antibodies, pre-incubation with the immunising peptide should abolish signal.

See the antibody specificity validation for IHC guide for the full validation approach specific to IHC applications.

Multi-channel IF workflows

Multi-channel IF is the workflow where proteinase antibody biology is most valuable — and most demanding. Because proteinases have zymogen and mature forms with distinct biological roles, imaging the two forms in different channels of the same section provides functional-state resolution that no single-antibody workflow can match.

Host species planning

The core rule for multi-channel IF: every primary antibody must be from a different host species. Two rabbit primaries cannot be co-detected because the anti-rabbit secondary binds both. Standard host combinations: rabbit + mouse + goat + chicken. Plan the antibody selection at the experiment-design stage — if you need to co-detect three proteinase targets, you need three primaries from three different host species, and this constrains your antibody choices before you order anything.

Secondary antibody cross-reactivity

Choose secondaries labelled as "highly cross-adsorbed" or "minimally cross-reactive" — these have been depleted against IgG from the other species in the panel. For a four-species panel, every secondary should be adsorbed against IgG from the other three species.

Sequential vs simultaneous incubation

Simultaneous: all primaries applied together, all secondaries applied together. Faster, works well when primaries are compatible. Sequential: one antibody complex at a time, with an image capture between rounds if the fluorophores would interfere. More laborious but essentially always works. Sequential is required when the two primaries share an isotype or host despite species labelling.

Nuclear counterstain

DAPI (blue channel) or Hoechst is the standard nuclear counterstain for IF, applied briefly before the final wash. Provides morphological context for the fluorescent signal.

Adapting for proteinase-specific epitopes

The choice of epitope on a proteinase determines what functional form is detected in IHC or IF. The same considerations that apply to Western blot antibody selection apply here, with the added complication that fixation may alter epitope accessibility differently for different domains.

Propeptide vs mature-form detection

Propeptide-region antibodies detect zymogen only — biologically relevant for detecting sites of proteinase synthesis but not sites of activity. Mature-form antibodies (mid-catalytic or C-terminal epitopes) detect both zymogen and mature forms, or (for neoepitope antibodies) only the activated mature form. In multi-channel IF, these two antibodies in different channels resolve zymogen from activated pool.

Membrane-anchored vs shed forms

For ADAMs and other membrane-anchored proteinases, the intact form is on the cell membrane and the shed form is in the extracellular space. A C-terminal (cytoplasmic tail) antibody detects only the intact membrane form; a catalytic-domain antibody detects both intact and shed. Permeabilisation affects whether the intracellular tail is accessible.

Complex-specific detection

For MMPs bound to TIMPs, complex-specific antibodies (raised against the complex conformation) exist for some pairings and give direct localisation of the inhibited pool. For most researchers, indirect detection (co-localisation of the enzyme and inhibitor in the same subcellular pool) is a practical substitute.

Superpooled multi-domain workflow in IHC/IF

Superpooled antibodies — the pooled multi-domain polyclonal reagent format developed at TPB — are particularly relevant to IHC/IF because they detect all functional forms of a proteinase simultaneously with domain-resolved signal when used in a multi-channel readout. For any experiment where the researcher wants total-target signal plus domain resolution in a single stain, the superpooled workflow is the appropriate choice. See the superpooled antibody usage protocol for the full protocol including the multi-channel IF configuration.

TPB validation status for IHC and IF

TPB catalog antibodies are validated primarily for Western blot and ELISA. IHC and IF validation is an ongoing internal program: individual antibodies are being systematically evaluated on positive-control tissues (typically stimulated macrophage-derived tissue for MMP targets, cathepsin-expressing tumour tissue for cathepsin targets, similar) with the standard positive/negative/no-primary control panel, and validation data is being added to individual product pages as it is generated.

For antibodies not yet IHC/IF validated on the product page, researchers should treat the antibody as un-validated for those applications and run their own validation before committing experimental samples. Contact TPB with the specific antibody and application you are considering; where IHC or IF data exists internally but has not yet been added to the product page, it may be available on request.

Frequently Asked Questions

Explore related topics in this cluster

• Proteinase IHC protocol— chromogenic IHC step-by-step
• Proteinase IF protocol— fluorescent IF step-by-step
• Antibody specificity validation for IHC— IHC control design
• Superpooled antibody usage protocol— multi-domain workflow for IHC/IF